Video

Urology Times 50 Innovations Series: Dr. Jennifer Linehan on HIFU for prostate cancer

Author(s):

Urology Times staff

"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.

As part of the Urology Times' 50th Anniversary Innovation Celebration, Jennifer Linehan, MD, discusses how high-intensity focused ultrasound (HIFU) revolutionized the way urologists treat localized prostate cancer. This techology, she emphasizes, creates another safe and effective minimally-invasive therapy for this population of patients. Linehan is an associate professor of urology and urologic oncology at the John Wayne Cancer Institute in Santa Monica, California.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
Related Content
Agreement reached for public reimbursement of Pluvicto in Canada
December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke
Pluvicto was approved by Health Canada in August 2022.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Adding CAN-2409 to radiation improves DFS in localized prostate cancer
December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke
“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
FDA grants clearance to NanoKnife System for prostate tissue ablation
December 9th 2024

FDA grants clearance to NanoKnife System for prostate tissue ablation

Hannah Clarke
The clearance is supported by data from the PRESERVE trial, which evaluated the safety and effectiveness of the NanoKnife System in patients with intermediate-risk prostate cancer.
FDA fast tracks PT217 for neuroendocrine prostate cancer
December 5th 2024

FDA fast tracks PT217 for neuroendocrine prostate cancer

Hannah Clarke
PT217 is currently under investigation in the phase 1/2 SKYBRIDGE trial in patients with neuroendocrine cancers.
© 2024 MJH Life Sciences

All rights reserved.